Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioRestorative Therapies (BRTX) Common Equity (2016 - 2025)

Historic Common Equity for BioRestorative Therapies (BRTX) over the last 15 years, with Q3 2025 value amounting to $2.2 million.

  • BioRestorative Therapies' Common Equity fell 7791.24% to $2.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.2 million, marking a year-over-year decrease of 7791.24%. This contributed to the annual value of $8.5 million for FY2024, which is 1472.34% down from last year.
  • As of Q3 2025, BioRestorative Therapies' Common Equity stood at $2.2 million, which was down 7791.24% from $4.8 million recorded in Q2 2025.
  • BioRestorative Therapies' Common Equity's 5-year high stood at $21.6 million during Q4 2021, with a 5-year trough of -$4.9 million in Q3 2021.
  • In the last 5 years, BioRestorative Therapies' Common Equity had a median value of $8.5 million in 2024 and averaged $7.1 million.
  • As far as peak fluctuations go, BioRestorative Therapies' Common Equity skyrocketed by 172201.12% in 2021, and later crashed by 7824.1% in 2023.
  • Over the past 5 years, BioRestorative Therapies' Common Equity (Quarter) stood at $21.6 million in 2021, then tumbled by 52.35% to $10.3 million in 2022, then fell by 2.78% to $10.0 million in 2023, then dropped by 14.72% to $8.5 million in 2024, then plummeted by 74.13% to $2.2 million in 2025.
  • Its Common Equity was $2.2 million in Q3 2025, compared to $4.8 million in Q2 2025 and $6.1 million in Q1 2025.